Genetic testing in patients with CVID can potentially guide therapy, as was the case in our study, such as the use of abatacept, infliximab, and rituximab in the treatment of autoimmune manifestations of CVID in patients with CTLA-4 and LRBA mutations. This evidence concerns the gene CTLA4 and common variable immunodeficiency.